CANTON, Mass. and SAN ANTONIO, April 30, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced today that the latest research on NuShield® and PuraPly® Antimicrobial will be presented at the Symposium on Advanced Wound Care Spring | Wound Healing Society (SAWC Spring | WHS) 2019 meeting, held May 7-11 in San Antonio.
Research highlights include two NuShield® podium presentations on the WHS track.
“Dehydrated Amnion Chorion Membranes Induce Broad-scale Changes in Kinase Activity of Endothelial Cells” will be presented by Miranda Burnette, Ph.D., John P. McQuilling, Ph.D., MaryRose Kammer, Kelly A. Kimmerling, and Katie C. Mowry on Wednesday, May 8 from 4:55 to 5:05 p.m. in Meeting Room 006 B-D.
“In Vivo Evaluation of Angiogenic Properties of a Dehydrated Amnion Chorion Membrane” will be presented by John P. McQuilling, Ph.D., MaryRose Kammer, Kelly Kimmerling, and Katie C. Mowry on Friday, May 10 from 10:40 to 10:50 a.m. in Meeting Room 007 D.
Educational opportunities at the Organogenesis booth (#407) will include a wet lab demonstration of the Organogenesis wound care product portfolio.
Organogenesis will also sponsor a lunch symposium called “Breaking Biofilms and Advancing Healing” on Wednesday, May 8 from 12 to 1:30 p.m.
“Each year, the Symposium on Advanced Wound Care and the Wound Healing Society provide invaluable forums for the clinical and research communities to discuss the latest developments in wound healing,” said Shabnam Vaezzadeh, MD, MPA, Vice President of Global Medical and Clinical Affairs for Organogenesis. “We look forward to sharing new medical and scientific evidence for our products with the wound care community.”
RESEARCH PRESENTATIONS OF INTEREST INCLUDE:
PODIUM PRESENTATIONS
Dehydrated Amnion Chorion Membranes Induce Broad-scale Changes in Kinase Activity of Endothelial Cells
Miranda Burnette, John P. McQuilling, MaryRose Kammer, Kelly A. Kimmerling, Katie C. Mowry
Date:Wednesday, May 8Time: 4:55 - 5:05 p.m. Location: 006 B-D
In Vivo Evaluation of Angiogenic Properties of a Dehydrated Amnion Chorion Membrane
John P. McQuilling, MaryRose Kammer, Kelly Kimmerling, Katie C. Mowry
Date: Friday, May 10Time: 10:40 - 10:50 a.m. Location: 007 D
POSTER PRESENTATIONS
In-vitro study evaluating the sustained released effects of antimicrobial products against Methicillin-resistant Staphylococcus aureus (MRSA)
Alexander Higa, Joel Gil, Jose Valdes, Michael Solis, Stephen C. Davis
Combined Sequential effect of purified native type I collagen plus polyhexamethylene biguanide, followed by placental allograft on chronic wounds of various etiologies: a case series
George Koullias
Use of dehydrated amnion/chorion membrane (dACM) to treat non-healing leg ulcers caused by pyoderma gangrenosum
Windy Cole
Use of dehydrated amnion/chorion membrane (dACM) in a slow healing trauma wound
Susan Rolniak St. John, Dawn Wang, Jodi Boory, Janie Hollenbach
Broad Proteomic Analysis of a Dehydrated Amnion Chorion Membrane
Miranda Burnette, John P. McQuilling, MaryRose Kammer, Kelly A. Kimmerling, Katie C. Mowry
Dehydrated Amnion Chorion Membranes Induce Broad-scale Changes in Kinase Activity of Endothelial Cells
Miranda Burnette, John P. McQuilling, MaryRose Kammer, Kelly A. Kimmerling, Katie C. Mowry
In Vivo Evaluation of Angiogenic Properties of a Dehydrated Amnion Chorion Membrane
John P. McQuilling, MaryRose Kammer, Kelly Kimmerling, Katie C. Mowry
About Organogenesis Holdings Inc.
Organogenesis is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. To learn more, please see www.organogenesis.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to new evidence regarding the efficacy of our products. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward looking statements. These risks and uncertainties include the fact that rapid technological change could cause our products to become obsolete and if we do not enhance our product offerings through our research and development efforts, we may be unable to effectively compete, and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of our Form 10-K for the year ended December 31, 2018. Although we may voluntarily do so from time to time, we undertake no commitment to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Press and Media Inquiries:
Press Inquiries:
Angelyn Lowealowe@organo.com
781-774-9364
Investor Inquiries:
Westwicke PartnersMike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500
Source: Organogenesis Holdings Inc.
